Asthma – Epidemiology Forecast to 2029
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Asthma is a common respiratory condition that affects the lungs. The airways in the lungs narrow and well, causing obstruction to the airflow (CDC, 2013; NHS, 2018). For some people asthma is mild, but in severe cases, people can experience life-threatening asthma attacks (Mayo Clinic, 2018). In most cases, the cause of asthma is unknown, and although there is no cure, medication can help control asthma (CDC, 2013). Asthma can develop at any stage of life. Often, in children, asthma can resolve during their teenage years; however, it is usually a long-term illness, especially if it first develops in adulthood (NHS, 2018).
GlobalData epidemiologists used age- and sex-specific lifetime diagnosed prevalence rates to forecast the lifetime diagnosed prevalent cases. GlobalData epidemiologists applied country-specific lifetime diagnosed prevalence rates of asthma, wherever available, to each country’s population to obtain the number of estimated lifetime diagnosed prevalent cases. Lifetime diagnosed prevalent cases were also segmented by severity of asthma.
The following data describes epidemiology of asthma cases. In 2019, the 7MM had 86,751,036 lifetime diagnosed prevalent cases of asthma. This is expected to increase to 89,414,720 cases by 2029, at an Annual Growth Rate (AGR) of 0.31%. The increase is driven by changes in the in the underlying population structure such as aging and population growth in the 7MM. In 2019, intermittent asthma was the most predominant severity in the 7MM. The US had the highest number of lifetime diagnosed prevalent cases of asthma. The development of more effective therapies, particularly for severe persistent and difficult-to-treat patients, would improve quality of life and reduce the frequency with which patients experience symptoms.
Scope
The Asthma Epidemiology Report and Model provide an overview of the risk factors and global trends of asthma in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
This report also includes a 10-year epidemiological forecast for the following segmentations in all across the 7MM: lifetime diagnosed prevalent cases of asthma; lifetime diagnosed prevalent cases of pancreatic cancer by severity.
The asthma epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
• The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Reasons to Buy
The Asthma Epidemiology series will allow you to:
Develop business strategies by understanding the trends shaping and driving the global asthma market.
Quantify patient populations in the global asthma market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for asthma therapeutics in each of the markets covered.
Understand magnitude of asthma population by severity.
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.